John Xu
Tanzania
Research Article
A Pooled Analysis of the Efficacy and Safety of Saxagliptin as Monotherapy in Patients with Type 2 Diabetes
Author(s): Boaz Hirshberg, Brian Bryzinski, John Xu and Nayyar IqbalBoaz Hirshberg, Brian Bryzinski, John Xu and Nayyar Iqbal
Objective: Saxagliptin is a once-daily, orally administered dipeptidyl peptidase-4 inhibitor, approved for the treatment of type 2 diabetes mellitus (T2DM). In 4 double-blind, placebo-controlled, phase 3 trials, saxagliptin 2.5 or 5 mg significantly reduced glycated hemoglobin (HbA1c) from baseline at 24 weeks. A pooled analysis of these clinical trials was conducted to assess the therapeutic profile of saxagliptin monotherapy.
Methods: A post hoc pooled analysis of 4 saxagliptin monotherapy trials in patients with T2DM was conducted to determine the consistency of treatment effects, assessed as change from baseline in HbA1c at week 24, in patient subgroups stratified by race, sex, age, and baseline HbA1c. Secondary end points included change from baseline at week 24 in fasting plasma glucose a.. View More»
